Member Login（https://members.medaus.com.au/）
Indemnity & Compensation Guidelines
Indemnity & Compensation Guidelines
Policy（https://www.medicinesaustralia.com.au/policy/） Strategic Agreement 2022-2027（https://www.medicinesaustralia.com.au/policy/strategic-agreement-2022-2027/）
Health Technology Assessment (HTA)（https://www.medicinesaustralia.com.au/policy/health-technology-assessment-hta/）
Access to Medicines Working Group (AMWG)（https://www.medicinesaustralia.com.au/policy/access-to-medicines-working-group-amwg/）
Clinical Trials（https://www.medicinesaustralia.com.au/policy/clinical-trials/） Clinical Trial Research Agreements（https://www.medicinesaustralia.com.au/policy/clinical-trials/clinical-trial-research-agreements/）
Indemnity & Compensation Guidelines（https://www.medicinesaustralia.com.au/policy/clinical-trials/indemnity-compensation-guidelines/）
Research & Development Taskforce (RDTF)（https://www.medicinesaustralia.com.au/policy/clinical-trials/research-development-task-force-rdtf/）
Teletrials（https://www.medicinesaustralia.com.au/policy/clinical-trials/tele-trials/）
Oncology Industry Taskforce（https://www.medicinesaustralia.com.au/policy/oncology-industry-taskforce/） Addressing the challenges of access to new cancer medications（https://www.medicinesaustralia.com.au/policy/oncology-industry-taskforce/addressing-the-challenges-of-access-to-new-cancer-medications/）
About the OIT（https://www.medicinesaustralia.com.au/policy/oncology-industry-taskforce/about-the-oit/）
Reports and resources（https://www.medicinesaustralia.com.au/policy/oncology-industry-taskforce/reports-and-resources/）
Pharma Australia Inclusion Group (PAIG)（https://www.medicinesaustralia.com.au/policy/pharma-australia-inclusion-group-paig/）
Policy Submissions（https://www.medicinesaustralia.com.au/policy/submissions/）
Regenerative Medicines Consortium Programme（https://www.medicinesaustralia.com.au/policy/regenerative-medicines-consortium-programme/）
What are the Voluntary Compensation Guidelines? As part of Medicines Australia’s role as the peak body for innovative pharmaceutical companies, we are the custodians of the Voluntary Compensation Guidelines. The Guidelines were established by us over 20 years ago and have become part of the clinical trial landscape across Australia.